You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD-1/PD-L1 agents

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

NSCLC Trial (BGB-A445, Docetaxel, Tislelizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Sep 6, 2023

Melanoma Trial (ONCOS-102, Balstilimab)

Not yet recruiting
  • Melanoma
  • ONCOS-102
  • Balstilimab
  • (no location specified)
Oct 24, 2022

Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma Trial in Worldwide (LY3300054,

Active, not recruiting
  • Solid Tumor
  • +4 more
  • Nashville, Tennessee
  • +14 more
Jul 21, 2022

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Recruiting
  • Hepatocellular Carcinoma
  • Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jul 23, 2021

Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 Trial in Scottsdale,

Active, not recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +7 more
  • Scottsdale, Arizona
  • +2 more
Nov 3, 2021

Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,

Recruiting
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Pembrolizumab
  • +5 more
  • Milan, Lombardia, Italy
  • +13 more
Jan 3, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital Fudan university
Jan 31, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

Recruiting
  • Oncology
  • +2 more
  • UV1
  • +2 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
Aug 15, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

Not yet recruiting
  • Lung Neoplasm
  • +2 more
  • Tumor samples
  • Bordeaux, France
    CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
Aug 28, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

Not yet recruiting
  • Extensive-Stage Small Cell Lung Cancer
  • Beijing, China
    Chinese PLA General Hospital
Aug 18, 2022

Immunotherapy in Upper Tract Urothelial Carcinoma

Not yet recruiting
  • Urothelial Carcinoma
  • Evaluation of anti-PD-(L)1 immunotherapy efficacy
  • (no location specified)
Oct 27, 2023

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

Recruiting
  • Esophageal Neoplasms
  • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Apr 21, 2022

Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

Not yet recruiting
  • Carcinoma, Hepatocellular
    • (no location specified)
    May 16, 2022